Skip to main content

Table 2 Association of NLR at baseline, at 6-weeks, and change at week 6 (±2 weeks) with treatment outcomes in multivariable Cox and Logistic regression models

From: Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

 

ORR (CR + PR)

PFS

OS

 

Total N/ N response

Adjusted-ORb

p-value

Total N/ N event

Adjusted-HRb

p-value

Total N/ N event

Adjusted-HRb

p-value

Continuous Ln(NLR) [baseline]

142/44

0.49 (0.22–1.09)

0.081

142/96

1.80 (1.14–2.86)

0.012

142/51

1.70 (0.99–2.94)

0.056

Continuous Ln(NLR) [6-weeks]a

134/44

0.22 (0.10–0.52)

0.001

117/72

3.61 (2.21–5.88)

<0.001

134/46

2.51 (1.71–3.69)

<0.001

NLR-change [6-weeks]a

 Decrease ≥25%

28/12

1.52 (0.49–4.68)

0.112

27/13

0.55 (0.26–1.18)

<0.001

28/6

0.33 (0.12–0.88)

0.004

 No change

58/21

1.00 (reference)

 

53/30

1.00 (reference)

 

58/18

1.00 (reference)

 

 Increase ≥25%

48/11

0.45 (0.18–1.16)

 

37/29

2.60 (1.53–4.39)

 

48/22

1.57 (0.83–2.99)

 
  1. Abbreviations: ORR objective response rate, CR complete response, PR partial response, OR odds ratio, PFS progression free survival, HR hazard ratio, OS overall survival
  2. aLandmark approach was used where OS and PFS were calculated from 6 weeks after therapy initiation. Patients who progressed before the 6 week landmark time were excluded for PFS analysis
  3. bAdjusted for line of therapy, number of IMDC risk factors, histology (clear cell RCC vs non-clear cell RCC); baseline Ln(NLR) was also included as a covariate for the analysis of NLR change at 6 weeks. Boldface numerical values indicate statistically significant results